Breakthroughs in Multiple Myeloma Treatment and Von Willebrand Disease Mechanisms

Spotlight on Acute Myeloid Leukemia

Busulfan-melphalan conditioning in newly diagnosed, transplant-eligible multiple myeloma; and use of spatial transcriptomics to probe the three-dimensional properties of multiple myeloma bone marrow microenvironments

How I Treat Wiskott-Alrich syndrome

Use of Marstacimab for Prophylaxis in hemophilia A and B; matched-donor allogeneic CD19 CAR-T in adult B-ALL; a new prognostic index for T-cell cutaneous lymphomas

Epstein-Barr virus genomic variants in human disease states, somatic GATA1 mutations and leukemia in Down syndrome, and new definitions for high-risk multiple myeloma

Review Series on Acute Lymphoblastic Leukemia (ALL)

Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AML

Diffuse large B-cell lymphoma’s long-term effects on immune profiles, plasminogen activation and prevention of venous thromboembolism, and PARP inhibitors in hematological malignancies carrying epigenetic mutations

“Ironing out” Tet2-mutant HSPCs; A CAR-T “license to kill” in T cell leukemia/lymphoma; insights on cHL genetics, through the lens of ctDNA

Targeting NPM1 in AML with a menin inhibitor; in primates, a CD137 ADC eliminates acute GVHD

How I Treat Series on Iron Overload in Hematologic Disorders

Early prediction of follicular lymphoma patients with poor survival; immune hotspots in aplastic anemia; role of allo-transplant for Hodgkin lymphoma in the checkpoint inhibitor era

Exogenous CD19 stimulation in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy, sequential rapid immune-assay in heparin-induced thrombocytopenia diagnosis, and new survival prediction models for chronic myelomonocytic leukemia

How I Treat series on Acute Myeloid Leukemia

Daratumumab maintenance in newly-diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in myeloproliferative neoplasms; and novel genetic loci associated with the risk of heavy menstrual bleeding

Hematopoietic stem cells with enhanced transplantability, ruxolitinib for refractory macrophage activation syndrome, and magrolimab in newly diagnosed acute myeloid leukemia

A JAK inhibitor for CRS and ICANS prevention; ChAdOx1-platelet interactions and post-vaccination arterial thrombosis; lineage switch, an emerging mechanism of leukemia relapse

Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factor

Review series on mantle cell lymphoma